Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Custom

Click to order products descending

Display 15 Products per page

Xolair
Read More
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma.
February 16, 2018
Find out more
Xofigo
Read More
Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases.
January 18, 2018
Find out more
Ximency
Read More
Ximency (Bristol-Myers Squibb) is a twice-daily fixed-dose combination of daclatasvir, a first-generation NS5A inhibitor; asunaprevir, an NS3 protease inhibitor; and beclabuvir, a non-nucleoside NS5B inhibitor. The combination is approved in Japan for the treatment of genotype 1 (GT-1) chronic hepatitis C virus infection.
November 6, 2017
Find out more
Xeljanz
Read More
While Xeljanz (tofacitinib; Pfizer/Takeda) demonstrated positive efficacy in its Phase III clinical trial

program, its future in psoriasis is uncertain.
October 17, 2017
Find out more
Xarelto
Read More
Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan.
March 15, 2018
Find out more
Xalkori
Read More
Xalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor
August 30, 2018
Find out more
Xadago
Read More
Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels.
June 21, 2018
Find out more
Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the US, 5EU, Japan, and RoW markets for tissue-engineered skin replacements (epidermal, dermal, and multilayer equivalents, and amniotic tissue grafts) and active wound repair modulators (growth factors, gene therapy agents, and stem cells).
September 23, 2020
Find out more
Wound Care: Advanced Dressings and Closure Products

$4,750.00

Over the past 25 years, there has been an explosion of knowledge regarding the basic science of wound healing and a trend toward more evidence-based medicine. In 2021, global sales of advanced wound care products totaled nearly $7.8bn, with advanced wound closure products accounting for more than half of sales and advanced dressings accounting for the remainder.
October 19, 2022
Find out more
Women’s Health: Market for Minimally Invasive Female Urinary Incontinence Devices

$3,750.00

This report focuses on minimally invasive therapy systems designed for the treatment of female urinary incontinence (UI); market segments covered include injectable urethral bulking agents, urethral sling systems, and neuromodulation systems.
December 19, 2016
Find out more
Women’s Health: U.S. Markets for Reproductive Management Products

$3,750.00

This report presents market and competitive analyses for selected leading contraceptive and fertility products as well as an overview of the most common types of contraceptives and fertility drugs/treatments available to women in the United States (U.S.) for reproductive management.

September 2, 2013
Find out more
Women’s Health: U.S. Markets for Female Urinary Incontinence Therapies

$3,750.00

This report focuses on minimally invasive therapy systems and medications designed for the treatment of female UI, including OAB pharmaceutical or drug treatments, injectable urethral bulking agents, and urethral sling systems, of which the OAB drug treatments market contributes the vast majority of revenues.
September 22, 2016
Find out more
Women’s Health: Trends and Opportunities in the U.S. Osteoporosis Management Market

$3,750.00

This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.
September 2, 2013
Find out more
Women’s Health: Osteoporosis Diagnostic Products

$3,750.00

This report provides analyses of products, markets, and competitors in the global market for osteoporosis diagnostic products. This market, as covered by the scope of this report, includes products that are used to diagnose osteoporosis, including bone densitometry systems and bone remodeling biochemical marker tests.
December 13, 2016
Find out more
When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *